Browse the corpus

REFERENCES Centers for Disease Control and Prevention (CDC), “Treatment of Tuberculosis. American Thoracic Society, CDC, and Infectious Diseases Society of America,” 2003, MMWR Recomm Rep , 52(RR-11):3-5. Available at file://www.cdc.gov/mmwr/preview/mmwrhtml/rr5211a1.htm Diacon AH, Donald PR, Pym A, et al, “Randomized Pilot Trial of Eight Weeks of Bedaquiline (TMC207) Treatment for Multidrug-Resistant Tuberculosis: Long Term Outcome, Tolerability, and Effect on Emergence of Drug Resistance,” Antimicrob Agents Chemother , 2012, 56(6):3271-6. [PubMed 22391540 ] Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al, “14-Day Bactericidal Activity of PA-824, Bedaquiline, Pyrazinamide and Moxifloxacin Combinations: A Randomised Trial,” Lancet , 2012, 380(9846):986-93. [PubMed 22828481 ] Diacon AH, Pym A, Grobusch M, et al, “The Diarylquinoline TMC207 for Multidrug-Resistant Tuberculosis,” N Engl J Med , 2009, 360(23):2397-405. [PubMed 19494215 ] Dooley KE, Park JG, Swindells S, et al, “Safety, Tolerability and Pharmacokinetic Interaction of the Antituberculous Agent TMC207 (Bedaquiline) With Efavirenz in Healthy Volunteers: AIDS Clinical Trials Group Study A5267,” J Acquir Immune Defic Syndr , 2012, 59(5):455-62. [PubMed 22126739 ] Rustomjee R, Diacon AH, Allen J, et al, “Early Bactericidal Activity and Pharmacokinetics of Diarylquinoline TMC207 in Treatment of Pulmonary Tuberculosis,” Antimicrob Agents Chemother , 2008, 52(8):2831-5. [PubMed 18505852 ] Villemagne B, Crauste C, Flipo M, et al, “Tuberculosis: The Drug Development Pipeline at a Glance,” Eur J Med Chem , 2012, 51:1-16. [PubMed 22421275 ] Topic 87509 Version 10.0 © 2013 UpToDate, Inc. All rights reserved. | Subscription and License Agreement | Release: 21.3 - C21.34 Licensed to: Morehouse School of Medicine | Support Tag: [1004-85.214.214.87-4FABCF92AE-S473950.14]